Amphastar Pharmaceuticals Inc
NASDAQ:AMPH

Watchlist Manager
Amphastar Pharmaceuticals Inc Logo
Amphastar Pharmaceuticals Inc
NASDAQ:AMPH
Watchlist
Price: 45.07 USD -0.9%
Market Cap: 2.2B USD
Have any thoughts about
Amphastar Pharmaceuticals Inc?
Write Note

Intrinsic Value

The intrinsic value of one AMPH stock under the Base Case scenario is 60.01 USD. Compared to the current market price of 45.07 USD, Amphastar Pharmaceuticals Inc is Undervalued by 25%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

AMPH Intrinsic Value
60.01 USD
Undervaluation 25%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Amphastar Pharmaceuticals Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for AMPH cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about AMPH?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Amphastar Pharmaceuticals Inc

Provide an overview of the primary business activities
of Amphastar Pharmaceuticals Inc.

What unique competitive advantages
does Amphastar Pharmaceuticals Inc hold over its rivals?

What risks and challenges
does Amphastar Pharmaceuticals Inc face in the near future?

Has there been any significant insider trading activity
in Amphastar Pharmaceuticals Inc recently?

Summarize the latest earnings call
of Amphastar Pharmaceuticals Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Amphastar Pharmaceuticals Inc.

Provide P/S
for Amphastar Pharmaceuticals Inc.

Provide P/E
for Amphastar Pharmaceuticals Inc.

Provide P/OCF
for Amphastar Pharmaceuticals Inc.

Provide P/FCFE
for Amphastar Pharmaceuticals Inc.

Provide P/B
for Amphastar Pharmaceuticals Inc.

Provide EV/S
for Amphastar Pharmaceuticals Inc.

Provide EV/GP
for Amphastar Pharmaceuticals Inc.

Provide EV/EBITDA
for Amphastar Pharmaceuticals Inc.

Provide EV/EBIT
for Amphastar Pharmaceuticals Inc.

Provide EV/OCF
for Amphastar Pharmaceuticals Inc.

Provide EV/FCFF
for Amphastar Pharmaceuticals Inc.

Provide EV/IC
for Amphastar Pharmaceuticals Inc.

Show me price targets
for Amphastar Pharmaceuticals Inc made by professional analysts.

What are the Revenue projections
for Amphastar Pharmaceuticals Inc?

How accurate were the past Revenue estimates
for Amphastar Pharmaceuticals Inc?

What are the Net Income projections
for Amphastar Pharmaceuticals Inc?

How accurate were the past Net Income estimates
for Amphastar Pharmaceuticals Inc?

What are the EPS projections
for Amphastar Pharmaceuticals Inc?

How accurate were the past EPS estimates
for Amphastar Pharmaceuticals Inc?

What are the EBIT projections
for Amphastar Pharmaceuticals Inc?

How accurate were the past EBIT estimates
for Amphastar Pharmaceuticals Inc?

Compare the revenue forecasts
for Amphastar Pharmaceuticals Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Amphastar Pharmaceuticals Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Amphastar Pharmaceuticals Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Amphastar Pharmaceuticals Inc compared to its peers.

Compare the P/E ratios
of Amphastar Pharmaceuticals Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Amphastar Pharmaceuticals Inc with its peers.

Analyze the financial leverage
of Amphastar Pharmaceuticals Inc compared to its main competitors.

Show all profitability ratios
for Amphastar Pharmaceuticals Inc.

Provide ROE
for Amphastar Pharmaceuticals Inc.

Provide ROA
for Amphastar Pharmaceuticals Inc.

Provide ROIC
for Amphastar Pharmaceuticals Inc.

Provide ROCE
for Amphastar Pharmaceuticals Inc.

Provide Gross Margin
for Amphastar Pharmaceuticals Inc.

Provide Operating Margin
for Amphastar Pharmaceuticals Inc.

Provide Net Margin
for Amphastar Pharmaceuticals Inc.

Provide FCF Margin
for Amphastar Pharmaceuticals Inc.

Show all solvency ratios
for Amphastar Pharmaceuticals Inc.

Provide D/E Ratio
for Amphastar Pharmaceuticals Inc.

Provide D/A Ratio
for Amphastar Pharmaceuticals Inc.

Provide Interest Coverage Ratio
for Amphastar Pharmaceuticals Inc.

Provide Altman Z-Score Ratio
for Amphastar Pharmaceuticals Inc.

Provide Quick Ratio
for Amphastar Pharmaceuticals Inc.

Provide Current Ratio
for Amphastar Pharmaceuticals Inc.

Provide Cash Ratio
for Amphastar Pharmaceuticals Inc.

What is the historical Revenue growth
over the last 5 years for Amphastar Pharmaceuticals Inc?

What is the historical Net Income growth
over the last 5 years for Amphastar Pharmaceuticals Inc?

What is the current Free Cash Flow
of Amphastar Pharmaceuticals Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Amphastar Pharmaceuticals Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Amphastar Pharmaceuticals Inc

Current Assets 482.6m
Cash & Short-Term Investments 217.8m
Receivables 132.1m
Other Current Assets 132.8m
Non-Current Assets 1B
Long-Term Investments 9.9m
PP&E 320.6m
Intangibles 600.8m
Other Non-Current Assets 77.5m
Current Liabilities 137m
Accounts Payable 31.8m
Accrued Liabilities 103.4m
Other Current Liabilities 1.8m
Non-Current Liabilities 641.2m
Long-Term Debt 586.9m
Other Non-Current Liabilities 54.4m
Efficiency

Earnings Waterfall
Amphastar Pharmaceuticals Inc

Revenue
712.9m USD
Cost of Revenue
-323.1m USD
Gross Profit
389.8m USD
Operating Expenses
-159.9m USD
Operating Income
229.9m USD
Other Expenses
-63.4m USD
Net Income
166.5m USD

Free Cash Flow Analysis
Amphastar Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

AMPH Profitability Score
Profitability Due Diligence

Amphastar Pharmaceuticals Inc's profitability score is 67/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Exceptional 3-Years Revenue Growth
ROE is Increasing
67/100
Profitability
Score

Amphastar Pharmaceuticals Inc's profitability score is 67/100. The higher the profitability score, the more profitable the company is.

AMPH Solvency Score
Solvency Due Diligence

Amphastar Pharmaceuticals Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
High Altman Z-Score
Long-Term Solvency
Low D/E
56/100
Solvency
Score

Amphastar Pharmaceuticals Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AMPH Price Targets Summary
Amphastar Pharmaceuticals Inc

Wall Street analysts forecast AMPH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AMPH is 62.73 USD with a low forecast of 55.55 USD and a high forecast of 73.5 USD.

Lowest
Price Target
55.55 USD
23% Upside
Average
Price Target
62.73 USD
39% Upside
Highest
Price Target
73.5 USD
63% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for AMPH?

Click here to dive deeper.

Dividends

Amphastar Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for AMPH is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

AMPH Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Amphastar Pharmaceuticals Inc Logo
Amphastar Pharmaceuticals Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

2.2B USD

Dividend Yield

0%

Description

Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. The company is headquartered in Rancho Cucamonga, California and currently employs 1,761 full-time employees. The company went IPO on 2014-06-25. The firm is primarily focused on developing, manufacturing, marketing and selling generic and injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (API) products. Its segments include Finished pharmaceutical products and API products. The Finished pharmaceutical products segment manufactures, markets and distributes Primatene Mist, glucagon, enoxaparin, naloxone, phytonadione, lidocaine, epinephrine, various critical and non-critical care drugs, as well as certain contract manufacturing. The API segment manufactures and distributes recombinant human insulin API and porcine insulin API for external customers and internal product development. Primatene Mist is an epinephrine inhalation product, which is indicated for the temporary relief of mild symptoms of intermittent asthma. Glucagon for injection emergency kit is indicated for the treatment of severe hypoglycemia.

Contact

CALIFORNIA
Rancho Cucamonga
11570 6th St
+19099809484.0
www.amphastar.com

IPO

2014-06-25

Employees

1 761

Officers

Chairman of the Board, Chief Scientist & COO
Dr. Ziping Luo Ph.D.
Co-Founder, President, CEO, Chief Scientific Officer & Director
Dr. Yongfeng Zhang Ph.D.
CFO, Executive VP of Finance, Treasurer & Director
Mr. William J. Peters M.B.A.
Executive VP of Sales, Marketing & Corporate Administration Center, Corporate Secretary and Director
Mr. Jacob Liawatidewi M.B.A.
Senior EVP of Production & EVP of Scientific Affairs
Mr. Rong Zhou M.S.
Senior Vice President of Human Resources & Corporate Communication
Mr. Dan Dischner M.B.A.
Show More
Executive VP of Regulatory Affairs & Clinical Operations
Tony Marrs M.B.A., M.P.H., M.S.
Show Less

See Also

Discover More
What is the Intrinsic Value of one AMPH stock?

The intrinsic value of one AMPH stock under the Base Case scenario is 60.01 USD.

Is AMPH stock undervalued or overvalued?

Compared to the current market price of 45.07 USD, Amphastar Pharmaceuticals Inc is Undervalued by 25%.

Back to Top